At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Neuroprotectants; Small molecules
- Mechanism of Action Glycine gated NMDA receptor antagonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 23 Jan 2001 No-Development-Reported for Stroke in Italy (Unknown route)
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 20 Aug 1999 New profile